Cara Therapeutics assumed with a Buy at CanaccordCanaccord analyst Sumant Kulkarni assumed coverage of Cara Therapeutics with a Buy rating and $33 price target. Cara recently received approval for Korsuva injection for chronic kidney disease-associated pruritus in adults on hemodialysis. ulkarni views the stock as "significantly undervalued" ahead of the upcoming launch of Korsuva IV in the U.S. given "solid partnerships" for the product with significant players in the space, the potential for rapid uptake as no other product is approved in the indication and Cara being positioned well to optimize the value of oral Korsuva, which still in development.Our Take: "Plenty of volatility to play with here." $CARA, Cara Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .